{"ticker": {"uuid": "07771777-8140-4565-81c7-e18c4477c62e", "symbol": "LPCN", "name": "Lipocine Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in Focus - Bull Pennant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPZ3hIQ1l6R3luLXp0NmVTcnJhX3dPZVZlUl9abi1SRG9kVk1vZ0liSERGSFo0WlJYeHVjWVVDUnc5N215V3Yyam1CTktRQlJPX3RGNkZianlyVDJLTWNsdmRYQktPb1JrQlNrQzVDUWRkR2VPcVEwRm1qOEFGTlVOVlRaZzE2eVFWNlN4dVZTS1JLdTN0dlEtVXZBVlhMSW0wa255LTBFeUZuU09wdTRjVjRUZXNxQlZNSkE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T18:42:34+00:00", "published_display": "07 Jul 2026 18:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lipocine Inc For: 30 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNdEJ4ZmdFcUNMUldReTZ5SS1NOUZhbWxFZjNiUHdGZEFESFdBaGNOSlBxbV9QVGRheHVPUGZTWjZmdFZZOHZMTE1qWG5OU1FrWnZ2RnZPTXgwTW05c0pHcUtXZGNUQTRSY1lXajBtRjd6ZE9FUHZsR3RhS0U2aFRoMUZnR1ZTaE5BOTU4OVRRMEpmQU5TcWdr?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-01T00:01:50+00:00", "published_display": "01 Jul 2026 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant", "summary": "Lipocine Inc. CEO Mahesh V. Patel was granted 52,781 stock options at an exercise price of $2.49 per share as part of his compensation. This grant increases his total reported stock option holdings to 227,214. The options will vest over time, with one-third vesting on June 29, 20", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-75fd29c8f6c9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T00:10:35", "published_display": "01 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "This article provides a brief overview of Lipocine Inc. (NASDAQ: LPCN) focusing on its \"Price to book forward\" metric. It appears to be a stub or data-centric page from TradingView, lacking detailed financial analysis or news content. The page highlights the stock's market status", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:10:54", "published_display": "28 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "This article focuses on the \"Price to earnings forward\" metric for Lipocine Inc. (NASDAQ: LPCN) as presented on the TradingView platform. It indicates that the specific financial data for this metric is displayed on the detailed company financial page. The content primarily lists", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:09:26", "published_display": "27 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "The article discusses the enterprise value to revenue forward of Lipocine Inc. (NASDAQ: LPCN). It is a financial data point available on TradingView, providing an overview of the company's financials, news, and community discussions.", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:16", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "The article \"Price to sales forward of Lipocine Inc. \u2013 NASDAQ:LPCN\" is from TradingView and indicates specific financial data for Lipocine Inc. The main content of the article, which would detail the actual \"Price to sales forward\" value, is not present in the provided text. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:09:13", "published_display": "27 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "This article provides financial data for Lipocine Inc. (NASDAQ: LPCN), specifically focusing on its Enterprise Value to EBITDA forward. The content appears to be a basic financial listing from TradingView, indicating no actual data was present in the provided snippet beyond the t", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:11:42", "published_display": "26 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc Actuals & Estimates (NASDAQ:LPCN)", "summary": "This article provides an overview of Lipocine Inc. (NASDAQ: LPCN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, and cash flow, alongside an", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:43", "published_display": "26 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LPCN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Lipocine Inc. (LPCN) stock, including its current price, market capitalization, and recent performance. It also details analysts' price targets, earnings estimates, and upcoming earnings report dates. The article emphasizes that the content is", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:48", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Institutional Confidence", "summary": "Lipocine Inc (LPCN) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 25.27%, a 35.40% quarterly increase, with James Simons being the largest institutional shareholder.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-25T00:09:55", "published_display": "25 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lipocine Inc (LPCN), detailing its current price momentum score, support and resistance levels for range-bound swing trading. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering buy, s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/technical", "source_name": "TradingKey", "published_at": "2026-06-23T11:41:03", "published_display": "23 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article states that Lipocine Inc (LPCN) has not yet disclosed relevant data regarding its revenue breakdown by business segments, regional revenue, or profit contribution. It provides current stock information for LPCN, including its price, market cap, and daily change.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:41:08", "published_display": "18 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lipocine Inc (LPCN) stock, focusing on its dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years and details multiple 17-to-1 reverse stock mergers that occurred on May 11, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:41:08", "published_display": "18 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lipocine Inc (LPCN) has an earnings forecast score of 7.00, placing it 313th out of 388 in the Biotechnology & Medical Research industry. Analysts have an average price target of $6.88 for LPCN, with a high of $7.00 and a low of $6.75, recommending a \"Buy\" trend. The company's ex", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:41:08", "published_display": "18 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine\u2019s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTFBsLXpQR3ZjOUlHaFhpSDM2Yk9TYVZ4QURHcFFVc2ZXSE1DSjlySG93NllQc0tvU1h0M09jMFFTcTZYUTRfSC0tVi1JcVlSS3pXMENGSDNCMTZkQXQ1VkNRY3BQclJRTUpqeHdqMTM2ZHZjbW5BMEE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) holds virtual KOL event on postpartum depression and LPCN 1154", "summary": "Lipocine Inc. (LPCN) hosted a virtual Key Opinion Leader (KOL) event on June 12, 2026, focusing on the unmet medical needs in postpartum depression and presenting the clinical profile of its investigational product, LPCN 1154. A detailed slide presentation from the event was file", "url": "https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-c00abca88dcc.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:55", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LPCN - Lipocine Inc Stock Price and Quote", "summary": "This page provides comprehensive stock information for Lipocine Inc. (LPCN), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and insider transactions. Key details include a last close price of $2.39, a market cap of $", "url": "https://finviz.com/stock?t=LPCN", "source_name": "Finviz", "published_at": "2026-06-05T16:11:10", "published_display": "05 Jun 2026 16:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) director Higuchi awarded right to buy 1,764 shares at $2.19", "summary": "Lipocine Inc. director John W. Higuchi has been granted derivative securities allowing him to purchase 1,764 shares of common stock at an exercise price of $2.19 per share. These rights will vest 100% one year from the grant date of June 3, 2026, and will expire on June 3, 2036. ", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-812b2d3d7d80.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (NASDAQ: LPCN) holders back directors and expand stock incentive plan", "summary": "Lipocine Inc. shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan, expanding the total shares authorized to 1,000,000 and increasing individual award limits. The shareholders also re-elected four directors, ratified Tanner LLC as their independent p", "url": "https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-a01b28516759.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) director awarded 1,764 stock options at $2.19 exercise price", "summary": "Lipocine Inc. director Jene Jill M. was granted 1,764 stock options with an exercise price of $2.19 per share, vesting 100% one year from the grant date and expiring on June 3, 2036. This grant is a routine equity compensation to align director incentives with shareholder value, ", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-75585b6cb16b.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Richard Dana Ono awarded 1,764 Lipocine (LPCN) stock options at $2.19", "summary": "Lipocine Inc. director Richard Dana Ono was granted 1,764 stock options at an exercise price of $2.19 per share. This equity award is compensation-related and not a direct purchase, with vesting occurring 100% one year from the grant date and an expiration date in 2036. Following", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-14e3dff645ae.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression", "summary": "Lipocine will host a virtual Key Opinion Leader (KOL) event on June 12, 2026, to present the Phase 3 topline results and clinical profile of LPCN 1154 for postpartum depression (PPD). The event will discuss the unmet needs in PPD treatment, treatment landscape, and gaps in care, ", "url": "https://www.tradingview.com/news/tradingview:530696bd33615:0-lipocine-to-host-virtual-kol-event-on-lpcn-1154-phase-3-data-for-postpartum-depression/", "source_name": "TradingView", "published_at": "2026-06-04T13:09:42", "published_display": "04 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154", "summary": "Lipocine Inc. is hosting a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression (PPD) and present the clinical profile of LPCN 1154 (BRLIZIO\u2122), their investigational oral brexanolone. The event will feature leading physicians who will review the cur", "url": "https://uk.finance.yahoo.com/news/lipocine-inc-host-virtual-kol-120000404.html", "source_name": "Market source", "published_at": "2026-06-04T12:09:42", "published_display": "04 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP", "summary": "Lipocine (LPCN) presented positive Phase 3 clinical data for its investigational drug, LPCN 1154 (oral brexanolone), for postpartum depression at the ASCP Annual Meeting. The results from the placebo-controlled trial, along with a presentation and poster from the meeting, were fu", "url": "https://www.tradingview.com/news/tradingview:1918c6e7738ea:0-lipocine-presents-phase-3-lpcn-1154-data-for-postpartum-depression-at-ascp/", "source_name": "TradingView", "published_at": "2026-05-26T21:09:18", "published_display": "26 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Lipocine Inc. Reports Material Event", "summary": "Lipocine Inc. filed an 8-K report detailing a scientific presentation rather than a financial event. On May 26, 2026, the company presented positive Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of C", "url": "https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-029e5b67e571.html", "source_name": "Stock Titan", "published_at": "2026-05-26T21:09:18", "published_display": "26 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase", "summary": "Lipocine Inc. announced that its management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM ET. The biopharmaceutical company, which uses a proprietary technology platform for effective oral drug delivery, ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lipocine-present-g-p-annual-120000283.html", "source_name": "Market source", "published_at": "2026-05-22T03:38:47", "published_display": "22 May 2026 03:38", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD", "summary": "Lipocine Inc. (LPCN) announced positive Phase III results for its postpartum depression (PPD) treatment. The study demonstrated rapid, significant, and durable efficacy with a strong safety profile in key subgroups, especially when an anomalous outlier site was excluded. Sufficie", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3353144:0-lpcn-excluding-an-outlier-site-rapid-and-durable-efficacy-with-strong-safety-was-demonstrated-in-ppd/", "source_name": "TradingView", "published_at": "2026-05-20T21:40:20", "published_display": "20 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine\u2019s postpartum depression drug data to be presented at ASCP", "summary": "Lipocine Inc. will present Phase 3 clinical data for its postpartum depression drug, LPCN 1154, at the American Society of Clinical Psychopharmacology Annual Meeting from May 26-29. Despite a significant stock decline and the failure of LPCN 1154 to meet its primary endpoint in a", "url": "https://m.uk.investing.com/news/stock-market-news/lipocines-postpartum-depression-drug-data-to-be-presented-at-ascp-93CH-4687588?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-19T15:10:45", "published_display": "19 May 2026 15:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting", "summary": "Lipocine announced that its Phase 3 LPCN 1154 data has been accepted for an oral presentation at the 2026 ASCP Annual Meeting. The presentation will highlight LPCN 1154's potential as a rapid-acting, at-home therapy for postpartum depression (PPD) with improved tolerability. A po", "url": "https://www.tradingview.com/news/tradingview:ae2d609015b9d:0-lipocine-phase-3-lpcn-1154-data-accepted-for-oral-presentation-at-2026-ascp-meeting/", "source_name": "TradingView", "published_at": "2026-05-19T13:09:19", "published_display": "19 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNU3RlamlkSWVYbWZ1Vk9WV2J5WWJQbkQ2RVdnTDZhSjJpVUZ5djU3R3FVRGlkR3ZneXhKS0xTN0h1bUo0UkpZZXdpWHQ1dXIxX1J5Z1VVYzRGaWZHY1U1VGdWWUlCeERCcmNLLWtKeTdjQTRtMmt5VUhRM0huOE9sMmdDQ1FDeW1mZjJfSW5XWGRxbGktM1pwbzBhUkJUM2Y3QlQ3eTZ5ZmJwSllPejkzSVlXTzFhT2ZtVnVvbDFIMG1BUXJuc1Utc095bTZWT1RCV25oUXpiQUNoUzVDdTFMMjZuTmE2VTJfT0lxSw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lipocine-lpcn-reports-q1-loss-191501721.html", "source_name": "Zacks", "published_at": "2026-05-07T19:15:01+00:00", "published_display": "07 May 2026 19:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lipocine-q1-earnings-snapshot-181107647.html", "source_name": "Associated Press", "published_at": "2026-05-07T18:11:07+00:00", "published_display": "07 May 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOc24zLUVIWHM3cGF4aFZKZkZVcmRsazVIR2tHUTBnQzdnUGM3VmExaVZ1SFJtclM3bWtPR0lvaGhMSThVYmhlUDNtZTdOM1JfWXBDQy1iNWRuM3psOVBZRE9CeWttZGFna0RMVTZoYnlGYVIyUEpCR0dGemRUSi1CQVF4cVpjb0NpTGZCaTZQLURFU2Z2RHUxbDNTNEdIUFYzQVBMMzVWcW4wT3NOczlZM2dFWlRrcmdmZkQ1UHg4S1k2djladzV6dFdGb1M3NFU?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Higuchi John W. buys Lipocine (LPCN) shares worth $81199", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOaWU4TnJJbENfT19XUkpsU3RwRWJHMFFzRkpBeDZEUEJFMFFEWTdubm9uX3ZtY0lxaUp3QXpkNFBmVkdjODVCMVE1TFZyQnBVdzRIeGZ1Z05vQ2VRY0lPX3h3TXZVY1NWcGd3bFN1ZHE2UC1SVWhxbjM4MV85ZnBpalBZOGhVUW5oWTdlSzlvUVh0V09zdkVocDJhX2U1VVRtQW84QktvZ19oTHN6X2FPbGE5cnlsazR0?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine CEO Patel acquires $50,749 in LPCN stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQbzZ6bTNyQ24wUUNHV1BtQzM0bFlxa1JQd3p1RUY5ZkhIMXVZLVViRTREVUJQVGtLODBKUHN5WUhrUUNUNmFUWWY1ZGRYMGsxNFd3YWpZS3FtOW1rOUVDdnNBQ3dLcmVWdk1ac1lkNkFQTlpjNGhWMXNBMEoxYk80WklTa203ZmFXR05GX0FmTzNLV0Z3SnRTTDhnQTNRREsxVmRIV3pMNjVnUGtBdlMtal93?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Higuchi John W. buys Lipocine (LPCN) shares worth $252,149", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOZlk0NGs5VERyTll1Q1pPNW40Y2lrckFUN0Q1d2hWUHZsZDZjNlBvOXR0VGZ2c0tGdjlPaHo2UE5BVm5ObTMyZmpFMDlUak55QjlYTHl1Y3JtYUprclZlMUMya19kQk45dnJHMWh0RkRxSnJpZ2hmVC1za0FHSWRMR296TVc2Nmx0NXhBWDZQS2tZSnVVRmt0LTd1Y0JSVjlOZGdRX0xVMENPZVZIRzAtZWVEbmxGWEJVYmc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Stock Plummets After Clinical Trial Disappointment", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5BNWp4YnhJeFZNamZBWmUzSkxlTlFWcEFuU1R1NktldDIzMlFWblRMVmZUdE1XV0RwTTJXNkluSUszWktManZ2aXEzRXJoNWNNc3Q4N00tdEtJMnExc1hiek51TDB6UUlGcVo5MEpOb0F2Zw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine stock tumbles after phase 3 trial misses endpoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQcW1KWlBsRFJrQkdSWjBEMDJqQVNnWXdFMnpwaEdocHZyeGFJcmhSOUo5bTgzLU1JaU5DTU9iemhzZFpCcjBFeGVWUDJvQzZzLXFZTWJzOFBGam1PamcyaWNoTjc3S1hDR21pem5zYzdKN3UzQXAwTVd0SmdENXZieGhSbmJFX3QtWFBXQV9DMEExZEZnekZqZzIyWTJ6d2lFejZrc1V3Z3RqS2NkTlpjSTJfQXVnOXdQelhLUg?oc=5", "source_name": "Investing.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lipocine Announces Financial Results for the Full Year Ended December 31, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPWDk4U2hUQURyTXFKQm1zQUR3RVJNS3JBZzZiaUctUFZia1JxSWoxcEdYNFIwalg2blU2dlhyNG9Rb0ZoeF9Ydmo2SzlFVEpPNGlCT1UxMC1wR0dLTkRCQ1JRSXFPR3kwTnhkcnN1cWtvWTlIVmJDQWhoTnFoTlVwS3ByMWQ0aFlRTXBOWndJLVNUNjZmRHhSa2Q0Y3Q2RUlraDRDZlJ0Z0FpQkNrV3NJdUFWV181ZjA1X2lIUWxVZE1ZV1lqUEhEUXBwZzNIQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB2NUZvZVBoSEdWOEkxUTdmMEw4ODhTNGNRaVJObTAtR1pkTVhJWUoweUJNb2l5UklZZnVvZ2t0RUJ2RFprVWl3ek80T0NTcnhnMEtJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:09:42+00:00", "published_display": "25 Apr 2025 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in Focus - Bull Pennant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPZ3hIQ1l6R3luLXp0NmVTcnJhX3dPZVZlUl9abi1SRG9kVk1vZ0liSERGSFo0WlJYeHVjWVVDUnc5N215V3Yyam1CTktRQlJPX3RGNkZianlyVDJLTWNsdmRYQktPb1JrQlNrQzVDUWRkR2VPcVEwRm1qOEFGTlVOVlRaZzE2eVFWNlN4dVZTS1JLdTN0dlEtVXZBVlhMSW0wa255LTBFeUZuU09wdTRjVjRUZXNxQlZNSkE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T18:42:34+00:00", "published_display": "07 Jul 2026 18:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lipocine Inc For: 30 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNdEJ4ZmdFcUNMUldReTZ5SS1NOUZhbWxFZjNiUHdGZEFESFdBaGNOSlBxbV9QVGRheHVPUGZTWjZmdFZZOHZMTE1qWG5OU1FrWnZ2RnZPTXgwTW05c0pHcUtXZGNUQTRSY1lXajBtRjd6ZE9FUHZsR3RhS0U2aFRoMUZnR1ZTaE5BOTU4OVRRMEpmQU5TcWdr?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-01T00:01:50+00:00", "published_display": "01 Jul 2026 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant", "summary": "Lipocine Inc. CEO Mahesh V. Patel was granted 52,781 stock options at an exercise price of $2.49 per share as part of his compensation. This grant increases his total reported stock option holdings to 227,214. The options will vest over time, with one-third vesting on June 29, 20", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-75fd29c8f6c9.html", "source_name": "Stock Titan", "published_at": "2026-07-01T00:10:35", "published_display": "01 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "This article provides a brief overview of Lipocine Inc. (NASDAQ: LPCN) focusing on its \"Price to book forward\" metric. It appears to be a stub or data-centric page from TradingView, lacking detailed financial analysis or news content. The page highlights the stock's market status", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:10:54", "published_display": "28 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "This article focuses on the \"Price to earnings forward\" metric for Lipocine Inc. (NASDAQ: LPCN) as presented on the TradingView platform. It indicates that the specific financial data for this metric is displayed on the detailed company financial page. The content primarily lists", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:09:26", "published_display": "27 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "The article discusses the enterprise value to revenue forward of Lipocine Inc. (NASDAQ: LPCN). It is a financial data point available on TradingView, providing an overview of the company's financials, news, and community discussions.", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:16", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "The article \"Price to sales forward of Lipocine Inc. \u2013 NASDAQ:LPCN\" is from TradingView and indicates specific financial data for Lipocine Inc. The main content of the article, which would detail the actual \"Price to sales forward\" value, is not present in the provided text. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:09:13", "published_display": "27 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Lipocine Inc. \u2013 NASDAQ:LPCN", "summary": "This article provides financial data for Lipocine Inc. (NASDAQ: LPCN), specifically focusing on its Enterprise Value to EBITDA forward. The content appears to be a basic financial listing from TradingView, indicating no actual data was present in the provided snippet beyond the t", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T23:11:42", "published_display": "26 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc Actuals & Estimates (NASDAQ:LPCN)", "summary": "This article provides an overview of Lipocine Inc. (NASDAQ: LPCN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, and cash flow, alongside an", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:43", "published_display": "26 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LPCN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Lipocine Inc. (LPCN) stock, including its current price, market capitalization, and recent performance. It also details analysts' price targets, earnings estimates, and upcoming earnings report dates. The article emphasizes that the content is", "url": "https://www.tradingview.com/symbols/NASDAQ-LPCN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:48", "published_display": "25 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Institutional Confidence", "summary": "Lipocine Inc (LPCN) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 25.27%, a 35.40% quarterly increase, with James Simons being the largest institutional shareholder.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-25T00:09:55", "published_display": "25 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lipocine Inc (LPCN), detailing its current price momentum score, support and resistance levels for range-bound swing trading. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering buy, s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/technical", "source_name": "TradingKey", "published_at": "2026-06-23T11:41:03", "published_display": "23 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article states that Lipocine Inc (LPCN) has not yet disclosed relevant data regarding its revenue breakdown by business segments, regional revenue, or profit contribution. It provides current stock information for LPCN, including its price, market cap, and daily change.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:41:08", "published_display": "18 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lipocine Inc (LPCN) stock, focusing on its dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years and details multiple 17-to-1 reverse stock mergers that occurred on May 11, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:41:08", "published_display": "18 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lipocine Inc (LPCN) has an earnings forecast score of 7.00, placing it 313th out of 388 in the Biotechnology & Medical Research industry. Analysts have an average price target of $6.88 for LPCN, with a high of $7.00 and a low of $6.75, recommending a \"Buy\" trend. The company's ex", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lpcn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:41:08", "published_display": "18 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine\u2019s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTFBsLXpQR3ZjOUlHaFhpSDM2Yk9TYVZ4QURHcFFVc2ZXSE1DSjlySG93NllQc0tvU1h0M09jMFFTcTZYUTRfSC0tVi1JcVlSS3pXMENGSDNCMTZkQXQ1VkNRY3BQclJRTUpqeHdqMTM2ZHZjbW5BMEE?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) holds virtual KOL event on postpartum depression and LPCN 1154", "summary": "Lipocine Inc. (LPCN) hosted a virtual Key Opinion Leader (KOL) event on June 12, 2026, focusing on the unmet medical needs in postpartum depression and presenting the clinical profile of its investigational product, LPCN 1154. A detailed slide presentation from the event was file", "url": "https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-c00abca88dcc.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:39:55", "published_display": "12 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LPCN - Lipocine Inc Stock Price and Quote", "summary": "This page provides comprehensive stock information for Lipocine Inc. (LPCN), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and insider transactions. Key details include a last close price of $2.39, a market cap of $", "url": "https://finviz.com/stock?t=LPCN", "source_name": "Finviz", "published_at": "2026-06-05T16:11:10", "published_display": "05 Jun 2026 16:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) director Higuchi awarded right to buy 1,764 shares at $2.19", "summary": "Lipocine Inc. director John W. Higuchi has been granted derivative securities allowing him to purchase 1,764 shares of common stock at an exercise price of $2.19 per share. These rights will vest 100% one year from the grant date of June 3, 2026, and will expire on June 3, 2036. ", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-812b2d3d7d80.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (NASDAQ: LPCN) holders back directors and expand stock incentive plan", "summary": "Lipocine Inc. shareholders approved the Sixth Amended and Restated 2014 Stock and Incentive Plan, expanding the total shares authorized to 1,000,000 and increasing individual award limits. The shareholders also re-elected four directors, ratified Tanner LLC as their independent p", "url": "https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-a01b28516759.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) director awarded 1,764 stock options at $2.19 exercise price", "summary": "Lipocine Inc. director Jene Jill M. was granted 1,764 stock options with an exercise price of $2.19 per share, vesting 100% one year from the grant date and expiring on June 3, 2036. This grant is a routine equity compensation to align director incentives with shareholder value, ", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-75585b6cb16b.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Richard Dana Ono awarded 1,764 Lipocine (LPCN) stock options at $2.19", "summary": "Lipocine Inc. director Richard Dana Ono was granted 1,764 stock options at an exercise price of $2.19 per share. This equity award is compensation-related and not a direct purchase, with vesting occurring 100% one year from the grant date and an expiration date in 2036. Following", "url": "https://www.stocktitan.net/sec-filings/LPCN/form-4-lipocine-inc-insider-trading-activity-14e3dff645ae.html", "source_name": "Stock Titan", "published_at": "2026-06-04T19:38:47", "published_display": "04 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine to Host Virtual KOL Event on LPCN 1154 Phase 3 Data for Postpartum Depression", "summary": "Lipocine will host a virtual Key Opinion Leader (KOL) event on June 12, 2026, to present the Phase 3 topline results and clinical profile of LPCN 1154 for postpartum depression (PPD). The event will discuss the unmet needs in PPD treatment, treatment landscape, and gaps in care, ", "url": "https://www.tradingview.com/news/tradingview:530696bd33615:0-lipocine-to-host-virtual-kol-event-on-lpcn-1154-phase-3-data-for-postpartum-depression/", "source_name": "TradingView", "published_at": "2026-06-04T13:09:42", "published_display": "04 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154", "summary": "Lipocine Inc. is hosting a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression (PPD) and present the clinical profile of LPCN 1154 (BRLIZIO\u2122), their investigational oral brexanolone. The event will feature leading physicians who will review the cur", "url": "https://uk.finance.yahoo.com/news/lipocine-inc-host-virtual-kol-120000404.html", "source_name": "Market source", "published_at": "2026-06-04T12:09:42", "published_display": "04 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine presents Phase 3 LPCN 1154 data for postpartum depression at ASCP", "summary": "Lipocine (LPCN) presented positive Phase 3 clinical data for its investigational drug, LPCN 1154 (oral brexanolone), for postpartum depression at the ASCP Annual Meeting. The results from the placebo-controlled trial, along with a presentation and poster from the meeting, were fu", "url": "https://www.tradingview.com/news/tradingview:1918c6e7738ea:0-lipocine-presents-phase-3-lpcn-1154-data-for-postpartum-depression-at-ascp/", "source_name": "TradingView", "published_at": "2026-05-26T21:09:18", "published_display": "26 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Lipocine Inc. Reports Material Event", "summary": "Lipocine Inc. filed an 8-K report detailing a scientific presentation rather than a financial event. On May 26, 2026, the company presented positive Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of C", "url": "https://www.stocktitan.net/sec-filings/LPCN/8-k-lipocine-inc-reports-material-event-029e5b67e571.html", "source_name": "Stock Titan", "published_at": "2026-05-26T21:09:18", "published_display": "26 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase", "summary": "Lipocine Inc. announced that its management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM ET. The biopharmaceutical company, which uses a proprietary technology platform for effective oral drug delivery, ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lipocine-present-g-p-annual-120000283.html", "source_name": "Market source", "published_at": "2026-05-22T03:38:47", "published_display": "22 May 2026 03:38", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LPCN: Excluding an outlier site, rapid and durable efficacy with strong safety was demonstrated in PPD", "summary": "Lipocine Inc. (LPCN) announced positive Phase III results for its postpartum depression (PPD) treatment. The study demonstrated rapid, significant, and durable efficacy with a strong safety profile in key subgroups, especially when an anomalous outlier site was excluded. Sufficie", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3353144:0-lpcn-excluding-an-outlier-site-rapid-and-durable-efficacy-with-strong-safety-was-demonstrated-in-ppd/", "source_name": "TradingView", "published_at": "2026-05-20T21:40:20", "published_display": "20 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine\u2019s postpartum depression drug data to be presented at ASCP", "summary": "Lipocine Inc. will present Phase 3 clinical data for its postpartum depression drug, LPCN 1154, at the American Society of Clinical Psychopharmacology Annual Meeting from May 26-29. Despite a significant stock decline and the failure of LPCN 1154 to meet its primary endpoint in a", "url": "https://m.uk.investing.com/news/stock-market-news/lipocines-postpartum-depression-drug-data-to-be-presented-at-ascp-93CH-4687588?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-19T15:10:45", "published_display": "19 May 2026 15:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting", "summary": "Lipocine announced that its Phase 3 LPCN 1154 data has been accepted for an oral presentation at the 2026 ASCP Annual Meeting. The presentation will highlight LPCN 1154's potential as a rapid-acting, at-home therapy for postpartum depression (PPD) with improved tolerability. A po", "url": "https://www.tradingview.com/news/tradingview:ae2d609015b9d:0-lipocine-phase-3-lpcn-1154-data-accepted-for-oral-presentation-at-2026-ascp-meeting/", "source_name": "TradingView", "published_at": "2026-05-19T13:09:19", "published_display": "19 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNU3RlamlkSWVYbWZ1Vk9WV2J5WWJQbkQ2RVdnTDZhSjJpVUZ5djU3R3FVRGlkR3ZneXhKS0xTN0h1bUo0UkpZZXdpWHQ1dXIxX1J5Z1VVYzRGaWZHY1U1VGdWWUlCeERCcmNLLWtKeTdjQTRtMmt5VUhRM0huOE9sMmdDQ1FDeW1mZjJfSW5XWGRxbGktM1pwbzBhUkJUM2Y3QlQ3eTZ5ZmJwSllPejkzSVlXTzFhT2ZtVnVvbDFIMG1BUXJuc1Utc095bTZWT1RCV25oUXpiQUNoUzVDdTFMMjZuTmE2VTJfT0lxSw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lipocine-lpcn-reports-q1-loss-191501721.html", "source_name": "Zacks", "published_at": "2026-05-07T19:15:01+00:00", "published_display": "07 May 2026 19:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lipocine-q1-earnings-snapshot-181107647.html", "source_name": "Associated Press", "published_at": "2026-05-07T18:11:07+00:00", "published_display": "07 May 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOc24zLUVIWHM3cGF4aFZKZkZVcmRsazVIR2tHUTBnQzdnUGM3VmExaVZ1SFJtclM3bWtPR0lvaGhMSThVYmhlUDNtZTdOM1JfWXBDQy1iNWRuM3psOVBZRE9CeWttZGFna0RMVTZoYnlGYVIyUEpCR0dGemRUSi1CQVF4cVpjb0NpTGZCaTZQLURFU2Z2RHUxbDNTNEdIUFYzQVBMMzVWcW4wT3NOczlZM2dFWlRrcmdmZkQ1UHg4S1k2djladzV6dFdGb1M3NFU?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Higuchi John W. buys Lipocine (LPCN) shares worth $81199", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOaWU4TnJJbENfT19XUkpsU3RwRWJHMFFzRkpBeDZEUEJFMFFEWTdubm9uX3ZtY0lxaUp3QXpkNFBmVkdjODVCMVE1TFZyQnBVdzRIeGZ1Z05vQ2VRY0lPX3h3TXZVY1NWcGd3bFN1ZHE2UC1SVWhxbjM4MV85ZnBpalBZOGhVUW5oWTdlSzlvUVh0V09zdkVocDJhX2U1VVRtQW84QktvZ19oTHN6X2FPbGE5cnlsazR0?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine CEO Patel acquires $50,749 in LPCN stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQbzZ6bTNyQ24wUUNHV1BtQzM0bFlxa1JQd3p1RUY5ZkhIMXVZLVViRTREVUJQVGtLODBKUHN5WUhrUUNUNmFUWWY1ZGRYMGsxNFd3YWpZS3FtOW1rOUVDdnNBQ3dLcmVWdk1ac1lkNkFQTlpjNGhWMXNBMEoxYk80WklTa203ZmFXR05GX0FmTzNLV0Z3SnRTTDhnQTNRREsxVmRIV3pMNjVnUGtBdlMtal93?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Higuchi John W. buys Lipocine (LPCN) shares worth $252,149", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOZlk0NGs5VERyTll1Q1pPNW40Y2lrckFUN0Q1d2hWUHZsZDZjNlBvOXR0VGZ2c0tGdjlPaHo2UE5BVm5ObTMyZmpFMDlUak55QjlYTHl1Y3JtYUprclZlMUMya19kQk45dnJHMWh0RkRxSnJpZ2hmVC1za0FHSWRMR296TVc2Nmx0NXhBWDZQS2tZSnVVRmt0LTd1Y0JSVjlOZGdRX0xVMENPZVZIRzAtZWVEbmxGWEJVYmc?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Stock Plummets After Clinical Trial Disappointment", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5BNWp4YnhJeFZNamZBWmUzSkxlTlFWcEFuU1R1NktldDIzMlFWblRMVmZUdE1XV0RwTTJXNkluSUszWktManZ2aXEzRXJoNWNNc3Q4N00tdEtJMnExc1hiek51TDB6UUlGcVo5MEpOb0F2Zw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine stock tumbles after phase 3 trial misses endpoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQcW1KWlBsRFJrQkdSWjBEMDJqQVNnWXdFMnpwaEdocHZyeGFJcmhSOUo5bTgzLU1JaU5DTU9iemhzZFpCcjBFeGVWUDJvQzZzLXFZTWJzOFBGam1PamcyaWNoTjc3S1hDR21pem5zYzdKN3UzQXAwTVd0SmdENXZieGhSbmJFX3QtWFBXQV9DMEExZEZnekZqZzIyWTJ6d2lFejZrc1V3Z3RqS2NkTlpjSTJfQXVnOXdQelhLUg?oc=5", "source_name": "Investing.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine Announces Financial Results for the Full Year Ended December 31, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPWDk4U2hUQURyTXFKQm1zQUR3RVJNS3JBZzZiaUctUFZia1JxSWoxcEdYNFIwalg2blU2dlhyNG9Rb0ZoeF9Ydmo2SzlFVEpPNGlCT1UxMC1wR0dLTkRCQ1JRSXFPR3kwTnhkcnN1cWtvWTlIVmJDQWhoTnFoTlVwS3ByMWQ0aFlRTXBOWndJLVNUNjZmRHhSa2Q0Y3Q2RUlraDRDZlJ0Z0FpQkNrV3NJdUFWV181ZjA1X2lIUWxVZE1ZV1lqUEhEUXBwZzNIQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lipocine (LPCN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB2NUZvZVBoSEdWOEkxUTdmMEw4ODhTNGNRaVJObTAtR1pkTVhJWUoweUJNb2l5UklZZnVvZ2t0RUJ2RFprVWl3ek80T0NTcnhnMEtJ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:09:42+00:00", "published_display": "25 Apr 2025 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 49, "sentiment_summary": {"positive": 9, "negative": 4, "neutral": 36, "score": 52, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 10.05, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.41, "latest_week": "2026-07-10", "one_week_move": 0.8, "four_week_move": 6.6, "twelve_week_move": -0.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.423467, "market_dynamics_buy_signal": false, "relative_strength": -52.775105, "fair_value_gap": -43.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.1285, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.8% over one week, +6.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "PR Newswire", "count": 3}, {"label": "Investing.com UK", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.8% over one week, +6.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in Focus - Bull Pennant"}], "updated_at": "2026-07-16T03:02:35.692835+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}